CLINICAL_TRIALS
trial_result
· 2014-07-30
Clinical Trial Update: Fifty Two Week Extension Trial of Org 50081 (Esmirtazapine) in the Treatment of Insomnia (P05708) [Phase 3]
Summary
Phase 3 52-week extension trial of esmirtazapine (Org 50081) for insomnia completed; results posted in 2014.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Insomnia | Phase 3 | Status: COMPLETED | Results posted: 2014-07-30